"We have developed a medicine for Type-II diabetes patients on Ayurvedic method, which does not have any side effect," Senior Principal Scientist A K S Rawat told PTI today.
Generally antigens affect body organs on the long run. But this drug contains anti-oxidants, which help in rebuilding process, he said.
Rawat said the initiative was taken by NBRI Director C S Nautiyal.
He said the drug has been introduced in tablet form. The Ayurvedic drug has been named 'BGR-34' and may cost Rs 500 for 100 tablets.
A combination of natural extracts, the drug has been jointly developed by two CSIR laboratories -- NBRI and the Central Institute for Medicinal and Aromatic Plant (CIMAP) -- both in Lucknow.
NBRI has given permission to a Delhi-based pharmaceutical firm for commercial manufacturing and marketing of the medicine.
"The drug has extracts from four plants mentioned in Ayurveda and that makes it safe," Rawat said.
He said tests carried on animals and related scientific study found it to be safe and effective with clinical trials showing 67 per cent success.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
